Hospital Universitario 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2018

  1. Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG

    Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 392-401

  2. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

2017

  1. Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido

    Enfermedades Infecciosas y Microbiologia Clinica

2016

  1. Management of infection and febrile neutropenia in patients with solid cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 6, pp. 557-570

  2. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

  3. SEOM Clinical Guideline for bone metastases from solid tumours (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1243-1253

2015

  1. Controversies in the treatment of invasive urothelial carcinoma: A case report and review of the literature Urological oncology

    BMC Urology, Vol. 15, Núm. 1

2013

  1. Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: A prospective, observational study

    Supportive Care in Cancer, Vol. 21, Núm. 11, pp. 3039-3049

2011

  1. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 16, pp. 2433-2439

  2. Psychometric properties of the Perform Questionnaire: A brief scale for assessing patient perceptions of fatigue in cancer

    Supportive Care in Cancer, Vol. 19, Núm. 5, pp. 657-666

2010

  1. Integration of panitumumab into the treatment of colorectal cancer

    Critical Reviews in Oncology/Hematology, Vol. 74, Núm. 1, pp. 16-26

2009

  1. Adjuvant chemotherapy for stages II, III and IV of colon cancer

    Clinical and Translational Oncology, Vol. 11, Núm. 8, pp. 526-533

  2. Development of a new questionnaire to assess patient perceptions of cancer-related fatigue: Item generation and item reduction

    Value in Health, Vol. 12, Núm. 1, pp. 130-138

2007

  1. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer

    Clinical Colorectal Cancer, Vol. 6, Núm. 10, pp. 691-699

  2. Update in the management of ovarian and cervical carcinoma

    Clinical and Translational Oncology, Vol. 9, Núm. 7, pp. 443-451

2001

  1. La oncología médica en el tratamiento de la enfermedad avanzada del carcinoma de endometrio

    Ciencia Ginecologika, Vol. 5, Núm. 6, pp. 266-276